In vivo, MYTX‐011 exhibited enhanced antitumor efficacy across several NSCLC xenograft models, including those with epidermal growth factor receptor (EGFR) and kirsten rat sarcoma virus (KRAS) mutations, and those that expressed c‐MET at various levels. The gene discussed is MET; the disease is non-small cell lung carcinoma.